Kassoum Kayentao, Aissata Ongoiba, Anne C Preston, Sara A Healy, Zonghui Hu, Jeff Skinner, Safiatou Doumbo, Jing Wang, Hamidou Cisse, Didier Doumtabe, Abdrahamane Traore, Hamadi Traore, Adama Djiguiba, Shanping Li, Mary E Peterson, Shinyi Telscher, Azza H Idris, William C Adams, Adrian B McDermott, Sandeep Narpala, Bob C Lin, Leonid Serebryannyy, Somia P Hickman, Andrew J McDougal, Sandra Vazquez, Matthew Reiber, Judy A Stein, Jason G Gall, Kevin Carlton, Philipp Schwabl, Siriman Traore, Mamadou Keita, Amatigué Zéguimé, Adama Ouattara, M'Bouye Doucoure, Amagana Dolo, Sean C Murphy, Daniel E Neafsey, Silvia Portugal, Abdoulaye Djimdé, Boubacar Traore, Robert A Seder, Peter D Crompton
BACKGROUND: Subcutaneous administration of the monoclonal antibody L9LS protected adults against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal antibody administered subcutaneously can protect children from P. falciparum infection in a region where this organism is endemic is unclear. METHODS: We conducted a phase 2 trial in Mali to assess the safety and efficacy of subcutaneous administration of L9LS in children 6 to 10 years of age over a 6-month malaria season...
April 26, 2024: New England Journal of Medicine